THE CAUSES OF LOOSE BOWEL movements in patients with irritable bowel syndrome with diarrhea (IBS-D) include organ level alterations of function such as acceleration of colonic transit, documented in ϳ45% of patients with IBS-D (13) , and intestinal secretory mechanisms (reviewed in Ref. 9 ). The latter include increased duodenal and rectosigmoid expression of secretory transmitters (e.g., 5-HT) measured by morphological studies, reduced expression of the serotonin reuptake protein, and fecal excretion of secretogranins or chromogranins (18, 19, 38) . There was also evidence of reduced expression of proabsorption mechanisms (e.g., mucosal PYY, somatostatin, and neuropeptide Y).
IBS has also been associated with changes in rectosigmoid mucosal mRNA expression of immune factors, barrier function, and mucus secretion (2, 5, 6, 10, 12, 14, 26, 43, 46, 48, 50, 51, 53) . The upregulated mechanisms measured initially by RNA sequencing in 9 patients with IBS-D were associated with changes in ion transport and included PDZD3 and GUCA2B (12) ; these results were largely confirmed in a replication study using RT-PCR in 47 patients with IBS-D (11) . PDZ adapter proteins are involved in multiple ion transport functions in the intestine, and GUCA2B is the gene controlling the endogenous uroguanylin that induces chloride secretion. We also demonstrated [with false detection rate correction (FDR)] abnormal expression of mRNA in rectosigmoid mucosal biopsies of receptors or neurotransmitters (P2RY4 and VIP), cytokines and complement components (C4BPA and CCL20), immune function (e.g., TNFSF15), and mucosal repair and cell adhesion (TFF1 and FN1).
Differences in jejunal mucosal expression (at gene and protein levels) and in the distribution of apical junction complex proteins (34, 35) , as well as reduced ZO-1 expression in HLA DQ2/8-positive patients with non-celiac IBS-D (46) , support the observed alterations in barrier mechanisms seen in colonic mucosa in patients with IBS-D.
In this study, our aim was to compare, in small intestinal mucosa of patients with IBS-D and controls with normal small intestinal mucosa, the expression of a larger complement of genes potentially associated with the pathobiology of IBS-D, including tight junction proteins, chemokines, innate immunity, ion channels, and transmitters.
METHODS
Ethical approval. The study was approved by Mayo Clinic Institutional Review Board on June 3, 2014 (IRB No. 14-002151), and an Study design. We appraised bowel functions and descending duodenal mucosal mRNA expression in 15 patients with IBS-D (by Rome III criteria) and 7 controls who had undergone clinically indicated duodenal biopsies (predominantly to exclude celiac disease in patients with iron deficiency), which were morphologically normal.
Patient selection. Patients were recruited by public advertisement or by invitation to participate from a database of ϳ1,200 patients with IBS living within ϳ120 miles of the Mayo Clinic in Rochester, MN. Inclusion criteria were based on symptoms using validated diary questionnaire that characterized IBS symptoms and particularly bowel functions (44) . Participants also completed the Hospital Anxiety and Depression Inventory (52) . These patients had been evaluated at Mayo Clinic, and alternative diagnoses such as inflammatory bowel disease, cancer, and celiac disease were excluded. The main exclusion criterium was intake of medications that could cause bleeding (owing to the need for duodenal biopsies). During a 14-day period (Ϯ4 days), the patients with known IBS-D completed a daily bowel pattern diary [that included the 7-point Bristol Stool Form Scale (30), ranging from 1 or hard lumpy stool to 7 or watery diarrhea] to record their bowel habits; they also recorded daily their average abdominal pain severity and worst pain severity using a 100-mm visual analog scale. Clinical details of the seven controls who underwent clinically indicated duodenal biopsies are shown in RESULTS (see Table 2 ).
Stored biospecimens. The biopsies from patients with IBS-D were obtained at baseline (before treatment) in a study of the effects of therapy with serum bovine immunoglobulin (results to be published elsewhere).
We used stored samples from seven patients who had consented to the use of biospecimens (for future research) in prior studies (Principal Investigator: Joseph A. Murray) conducted at Mayo Clinic in Rochester, MN. These samples were from patients who underwent biopsies for clinical indications such as iron deficiency, with no evidence of small intestinal abnormality on biopsy. We chose to study "disease controls," most of whom had diarrhea that was not caused by celiac disease and did not fulfill criteria for IBS-D, to control for the presence of diarrhea. In this pilot study, we considered it was important to identify differences in expression that were not caused by the diarrhea per se.
Biopsies were preserved in a solution of RNAlater and stored at Ϫ80°C until the time of assay of gene expression.
Selection of genes of interest. We developed a custom profile including 89 genes (reflecting tight junction proteins, chemokines, innate immunity, ion channels, and transmitters; Table 1 ), extending from the previous 19 gene profile (12) as well as housekeeping (HKG) genes for normalization (B2M, ACTB, and GAPDH). Subsequently, we included SCN9A (NHE3) and CFTR expression in view of their known roles in the absorption of Na ϩ and secretion of Cl Ϫ ions, respectively. In addition, controls monitored DNA contamination, and first strand synthesis and PCR efficiency were included to check for sample quality and reaction quality.
Thus, the RT 2 -Profiler-PCR-Array data examined 96 genes on 22 samples (n ϭ 15 IBS-D patients and 7 healthy controls). Out of the 96 genes, two were identical (CCBL2, used for quality control), three were the housekeeping genes (B2M, ACTB, and GAPDH), and another three (HGDC, RTC, and PPC) were assay controls. Therefore, the custom array analysis focused on 89 genes.
Gene expression method by RT 2 PCR array. Mature RNA was isolated using the RNAeasy Extraction Kit (Qiagen) according to the manufacturer's instructions. All RNA integrity number values (measured using Agilent QC) were 9.5-10, confirming excellent RNA quality. RNA (500 ng) was reverse transcribed using a cDNA conversion kit, and cDNA in combination with RT 2 SYBR Green qPCR Mastermix (Qiagen) was used on a Custom RT 2 Profiler PCR Array. PCR was performed on a ViiA7 thermocycler (Applied Biosystems, Life Technologies, Grand Island, NY) and, finally, relative expression was determined using data from the real-time cycler and the ⌬⌬ CT method. Individual RT 2 qPCR Primer Assays (Qiagen) for SCN9A (NHE3) and CFTR expression were used under the same conditions as the custom array plate (i.e., starting amount of RNA, cDNA synthesis, thermocycling conditions, and analysis software). The following assays were applied for the individual assays: SCN9A (PPH11615E), CFTR (PPH01387F), B2M (PPH01094E), ACTB (PPH00073G), and GAPDH (PPH00150F).
Thus a total of 91 genes of interest were evaluated in the mucosal biopsies.
To control for DNA contamination introduced during reaction setup, a no template control (NTC) reaction replacing template with water as well as a no reverse transcription (NRT) reaction were run with the assays.
The mRNA expressions were assayed in triplicate, and the mean value was used for the statistical analysis.
Data and statistical analyses. Calculation of the threshold cycle (C T) was determined for each well. Briefly, using the ViiA7 Software on the real-time machine, baseline was defined by choosing the automated baseline option, and threshold was defined manually using the log view of the amplification plots. The threshold value was chosen above the background signal, but within the lower one-third to lower one-half of the linear phase of the amplification plot. In our study, the threshold was chosen at 0.16 for all plates. C T values for all wells were exported to Excel and analyzed through Qiagen's Data Analysis Center (http://www.qiagen.com/us/shop/genes-andpathways/data-analysis-center-overview-page).
Delta C T (⌬CT) was calculated between gene of interest and an average of housekeeping genes (B2M, ACTB, and GAPDH), followed by delta delta CT (⌬⌬CT) calculations [⌬CT(IBS-D) Ϫ ⌬CT(health)]. Fold change was calculated using 2
Ϫ⌬⌬CT formula. The P values (P Ͻ 0.05) were reported based on t-test, and the q values were computed to reflect statistical significance with FDR correction (42) .
Protein expression in duodenal mucosa. Nuclear and cytosolic lysates were isolated from human colonic biopsies using a subcellular fractionation protocol supplied by Abcam. Briefly, tissue biopsies were homogenized in RIPA Lysis buffer with added inhibitors (Santa Cruz Biotechnology, Dallas, TX) and centrifuged at 720 G. The pelleted nuclear proteins were then sonicated in additional RIPA lysis buffer to resuspend. The nuclear pellet supernatant was recentrifuged at 10,000 g and the resulting supernatant contained the cytosolic and membrane fraction. Concentrations were determined using the Bradford reagent according to the instructions of the supplier (Sigma, St. Louis, MO).
PPP2R5C protein measurements by Western blots. Nuclear lysates were separated using 4 -15% Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA) and blotted onto nitrocellulose membranes. The membranes were blocked with 5% milk in phosphate buffered saline (PBS)/0.2% Tween, after which PPP2R5C primary antibody (ab94633_1:1,000; Abcam, Cambridge, MA) was applied overnight at 4°C. ␣-Actin (A2066_1:1,000; Sigma) was used for normalization of protein loading. Membranes were washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (donkey or goat anti-rabbit; Santa Cruz Biotechnology) and visualized with Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences, Pittsburgh, PA) and autoradiography. Band densities were quantified with the ImageJ (40) .
Enzyme-linked immunosorbent assay. All duodenal biopsy extracts were used at a common concentration (1 g/l). Fifty microliters were used to assay INADL, MAPKAPK5, and MAGI1, (MyBioSource, San Diego, CA) whereas 100 l was used for the housekeeping gene phosphoglycerate kinase 1 (PGK1; LifeSpan Biosciences, Seattle, WA), which has been recommended as the preferred gene [over ␤-actin (ACTB) and ␤2-microglobulin (␤2M)] in the context of inflammatory bowel diseases (29) . Enzyme-linked immunosorbent assay (ELISA) kits were used for all these protein assays following the manufacturer's instructions. Samples were run in duplicate and spike recoveries were prepared in kit assay buffer at two concentration levels to verify performance.
Pathway and cluster analyses. We used a publicly available informatics tool to appraise the potential pathways or clustered mechanisms that are altered in the duodenal mucosa of patients with IBS-D, relative to controls. The Lens for Enrichment and Network Studies (LENS) of proteins provides interactome analysis of the list of human genes examined in this study to explore the network of proteinprotein interactions that connects them (23) . LENS computes associations of the genes in the interactome to pathways and assesses statistics of network connectivity of these genes compared against connectivity of randomly selected genes. Sources of data for the network generation are direct (biophysical) interactions from HPRD and BioGRID, and pathways are obtained from Reactome (http://severus.dbmi.pitt.edu/LENS/index.php). 
Significance analysis of microarray for gene sets analysis of gene expression and pathways.
Gene-set analysis evaluates the expression of biological pathways, or a priori defined gene sets rather than that of single genes, in association with a binary phenotype, and it is of great biologic interest in many DNA microarray studies. Gene Set Enrichment Analysis (GSEA) has been applied widely as a tool for gene set analyses, but it was not applicable for a small gene set in our study. We used an alternative method, more appropriate for targeted gene studies, by extending the single gene analysis method, Significance Analysis of Microarray (SAM), to Gene-Set Analyses (SAM-GS). Briefly, CT data were converted to expression data as follows: expression ϭ [2ˆ(ϪAvg. For pathway investigation, we also included the gene set subcatalogs C1 and C2 from MolecularSignatures Database (MSigDB) v5.1, a collection of annotated gene sets for use with GSEA software (http://www.broad.mit.edu/gsea). The C1 catalog includes gene sets corresponding to human chromosomes and cytogenetic bands, while the C2 catalog includes gene sets that are involved in specific metabolic and signaling pathways collected from various sources such as online pathway databases, publications in PubMed, and knowledge of domain experts. SAM-GS divides the C1 and C2 catalogs into 308 pathways, which were included in our analyses, so that, in total, we had 150 pathways/gene sets based on the 89 genes under consideration (16, 17, 32) .
RESULTS

Patients.
We studied 15 patients with IBS-D [Rome III positive: 2 male (M), 13 female (F); mean age 40.3 Ϯ 2.3 yr; mean body mass index (BMI) 34.3 Ϯ 3.0 kg/m 2 ] and 7 controls (2M,5F; 40.7 Ϯ 6.9 yr; P ϭ ns) who were negative for celiac disease. Bowel function and abdominal pain scores of the patients with IBS-D are shown in Table 2A . Clinical details of the seven controls who underwent clinically-indicated duodenal biopsies are shown in Table 2B .
mRNA fold change in duodenal mucosa from IBS relative to healthy controls. The mean (and 95% CI) fold changes (based on 2 Ϫ⌬⌬ CT ) in IBS-D and subgroups of IBS-D patients relative to healthy controls are illustrated in Table 3 and Fig. 1 . Table  3 There were other genes that showed numerical (nonsignificant) changes in expression (P Ͼ 0.05, Ͻ 0.1). Thus there was numerically increased expression in duodenal mucosa from IBS-D patients compared with controls for the following:
1) SLC10A2 (the gene for the bile acid transporter, 2.01-fold, P ϭ 0.093);
2) CLDN1 (claudin, a tight junction protein,1.43-fold, P ϭ 0.066);
3) KITLG (kit ligand, a determinant of development of interstitial cells of Cajal, 1.38-fold, P ϭ 0.074); 4) MPP5 (membrane protein, palmitoylated 5, involved in polarization of differentiating cells, 1.35 fold, P ϭ 0.070); 5) PVRL3 (poliovirus receptor-related 3, 1.22-fold, P ϭ 0.075); and 6) AHR (aryl hydrocarbon receptor, which regulates xenobiotic-metabolizing enzymessuch as cytochrome P450, 1.22-fold, P ϭ 0.053).
In contrast, the following were associated with numerically (not significantly) reduced expression in IBS-D duodenal mucosa compared with controls: CD3E (CD3-epsilon chain involved in T cell surface glycoprotein, Ϫ1.38-fold, 0.0.088); and TPSAB1 (tryptase alpha/beta 1, Ϫ1.61-fold, P ϭ 0.097).
Clustering analysis of pathways and mechanisms. Having identified the nominally, univariately significant upregulation or downregulation of genes in the mucosa, we applied LENS analysis, and plotted connectivity among the genes associated with barrier, T lymphocytes, and cytokines (Fig. 2) , focusing only on the genes that were nominally (P Ͻ 0.05) upregulated or downregulated. Among the 14 nominally upregulated genes, clustering of the barrier-associated mechanisms and related PDZ domains (TJP1, TJP2, TJP3, CLDN4, INADL, and MAGI1) was noted; among the seven downregulated genes, a cluster of immune function (chemokine, Toll-like receptor, and interleukin), specifically CCL20, TLR1, IL1B, and TLR8, was observed. It is relevant to note that FDR-corrected increased expression was identified in INADL and MAGI1.
SAM-GS analysis. The analysis results (Table 4) show the P value and q value of each gene set, based on the permutation test for no association between the gene expression of the gene set and the binary phenotype (IBS-D and control). The results are shown in order of the nominal P value.
The P value (P ϭ 0.185) of the test evaluating the entire 89 gene set shows no association between the gene expression of the gene set and phenotype.
However, there were several genes with univariate significance (see q values in Table 3 ) that were represented in pathways identified in the SAM-GS analysis, specifically in immune function (IL-15) and MAP kinase-activated protein kinase (MAPAPK5). These genes, found in gene-sets by SAM-GS, showed a trend (P values between 0.02 and 0.105) but not a statistically significant association to the phenotype.
Mucosal protein expression. Western blot analysis of duodenal mucosa from six healthy controls and seven patients with IBS-D who randomly selected from the same patient group was used to assess protein expression of PPP2R5C. This protein was selected as it showed increased mRNA fold expression (see Table 3 ). Figure 3 shows the increased protein expression including the appearance of the expression of PPP2R5C relative to the housekeeping protein, actin. The difference in expression between IBS-D group and biopsy-negative controls was statistically significant (P ϭ 0.044).
Expression of other mucosal proteins (INADL, MAGI1, and MAPKAPK5) using ELISA measurement was applied to duodenal biopsy extracts from 15 patients with IBS-D and 6 controls (Table 5 ). There were very similar concentrations of the housekeeping gene PGK1 in the patients and controls. Numerical differences in protein expression of one of those tested, INADL, did not reach statistical significance: median 9.4 ng/ml in patients with IBS-D relative to controls, median 5.8 ng/ml (P Ͼ 0.05).
DISCUSSION
Our study evaluated expression in small intestinal mucosa of genes related to tight junctions, chemokines, innate immunity, ion channels, and transmitters in 15 patients with IBS-D and 7 controls with proven normal biopsies based on histopathology. With FDR correction, the following genes were significant (q Ͻ 0.05): INADL, MAGI1, PPP2R5C, MAPKAPK5, TLR3, and IL-15, all of which were upregulated in IBS-D relative to controls. The fold expression alterations in mechanisms of ion transport (INADL and MAGI1), epithelial response to damage (PPP2R5C), and immune mechanisms (TLR3 and IL15) in small bowel mucosa suggest that differential expression of small intestinal mucosa in IBS-D may be important in the biological mechanisms in IBS-D and certainly deserve further study. The findings on LENS cluster analysis of barrier and ion transport (both upregulated) and immune function (downregulated) are summarized in Fig. 4 . Although the q values in the pathway analysis using SAM-GS do not show significant associations of pathways with phenotype, it is relevant to note that the MAPKAPK5 pathways and CR-immune function pathways show interesting trends (not statistically significant) and include upregulated genes in the comparisons between IBS-D and controls (specifically MAPKAPK5 and IL15). The upregulated or downregulated gene expressions suggest, in some cases, that the changes may represent reciprocal or compensatory changes within the same biological functions. One example of reciprocal changes in expression is downregulation of TLR1, TLR8, and CD3E in contrast to the upregulation of TLR3; another example where the changes may simply reflect reciprocal changes in expression is downregulated IL-1B and upregulated IL-15. On the other hand, there is consistent upregulation of barrier function gene expression, as shown by the results for ZO-1, 2, and 3, claudin-1 and -4, and MAPKAPK5. ZO and claudin genes are directly related to intercellular junction proteins, whereas MAPKAPK5 controls a kinase involved in growth factor-stimulated cell proliferation and muscle cell differentiation. IL-15 plays a key role in intraepithelial lymphocyte function and in some forms of intestinal inflammation (1, 33) .
The biological significance of the upregulation of barrier function is unclear. There are other changes in expression that may conceivably be associated with increased fluid or electrolyte secretion, such as the upregulation of the following:
1) InaD-like (Drosophila) gene, for which there is a human analog INADL gene producing a protein (39) , which encodes multiple PDZ domain proteins that may enhance ion transport, and a related tight junction-associated multi-PDZ protein PATJ (PALS1-associated TJ protein) that connects and stabilizes apical and lateral components of tight junctions in human intestinal cells (36) ;
2) Membrane-associated guanylate kinase MAGI1, which influences cell junction, interaction with acid-sensing ion channel (sensation) and PDZ domain (ion transport);
3) SONS1 [Sons of Sevenless (Drosophila) homolog] 1, which is a guanine nucleotide exchange factor; it is worth noting that guanine nucleotide exchange factor, Epac (Exchange protein directly activated by cAMP), appears to be involved in intestinal secretion (22, 25, 41) . However, there is no evidence in the literature that this gene has functional effects in humans.
4) SLC9A3 [Solute Carrier Family 9, Subfamily A, Member 3), which encodes for the NHE3 channel is possibly upregulated (fold change 1.54, q ϭ 0.153). If the increased expression results in increased protein, it would be expected that there would be greater Na ϩ absorption which may conceivably reduce fluid secretion in contrast to some of the other secretory mechanisms that may be upregulated. Overall, our current studies support upregulation of intestinal ion transport mechanisms. This is consistent with increased mRNA expression of PDZ-related mechanisms previously demonstrated in colonic mucosa (11, 12) . These data suggest increased ion transport, possibly leading to water and electrolyte secretion, that is partly counteracted by the increased expression of barrier function mechanisms. These observations emphasize the importance of thorough characterization of the phenotype in patients with IBS-D, given the different peripheral mechanisms that result in the phenotype of IBS-D (8, 9) . Future studies will be enhanced by further characterization of the baseline pathophysiological phenotype in patients with the symptom phenotype of IBS-D, such as bile acid diarrhea, rapid small bowel or colonic transit, and upregulated mucosal immune mechanisms.
In addition to the changes in mRNA expression, we also observed significantly increased expression of PPP2R5C as demonstrated by Western blot, and a numerical increase in the protein level of INADL by ELISA, although this did not reach statistical significance. The concentrations of the housekeeping gene in the duodenal biopsy lysates used from the two groups were similar in the ELISA assays, suggesting that the absence of statistically significant differences in the protein concentrations is not the result of technical error in the measurements. On the other hand, the pooled standard deviation of INADL in the two groups was large (19.7 pg/ml), and the estimated sample size to prove statistical difference for 2.5-or 1.5-fold differences in concentration of INADL relative to control (median 5.83 pg/ml) would be respectively 30 and 81 per patient group, respectively. Therefore, our study was underpowered to appraise differences in the proteins measured by ELISA.
The intestinal mucosa contains a pool of histamine that rapidly turns over and that appears to be derived largely from a non-mast cell source. Histamine inhibits chloride absorption, inducing bicarbonate secretion in ileal mucosa and influencing SAM-GS, Significance Analysis of Microarray to Gene-Set Analyses; GS size, number of genes in the gene set/pathway; GS P value, permutation test for no association between the gene expression of the gene set and the binary phenotype (IBS-D compared with controls); GS q value, to account for multiple comparisons when multiple gene sets are tested, one might consider FDR instead of type I error probability; oGS, original number of genes in the pathway/gene set (for example, there were 106 genes in the NFKB_INDUCED pathway, where 7 genes from our study were found); Genes in Pathway, the genes in our study found in the pathway/gene set (for example, there are 7 genes from our study overlapping with NFKB_INDUCED pathway; the genes are CCL20, FN1, IL15, IL1B, IL6, IL8, and TNF).
chloride/bicarbonate exchange, largely by actions mediated by histamine H 1 receptors (31). Chromogranin A (ChgA), an acidic protein found in large dense-core secretory vesicles, functions as a monoamine-binding protein that facilitates the regulated endocrine secretion of large amounts of monoamines from enteroendocrine cells (20) . The increased gene expression of the histamine metabolizing enzyme, HNMT, may also serve as a compensatory mechanism to reduce the effects of histamine released from enteroendocrine cells or from mast cells whose density is increased in the jejunal mucosa of non-atopic IBS-D patients (47) .
The latter investigation by Vicario et al. (47) identified a number of immune-modulating mechanisms, suggesting increased humoral immune function in the jejunal mucosa of patients with IBS-D. This is consistent with several alterations in gene expression for immune regulation and T-cell function in our current study. In addition, the increased expression for the enzyme metabolizing histamine is consistent with increased release or supernantant content of histamine from colorectal mucosal biopsies from patients with IBS (3, 4, 7, 15, 28) . This overexpression of HNMT may conceivably provide a natural metabolism of histamine, which may be produced and secreted in larger quantities by the increased numbers of mast cells. This natural reduction in histamine may serve as an alternative to achieve the beneficial effects on symptoms of the mast cell stabilizer and antihistaminic medication ketotifen (28) and the selective H1 receptor antagonist ebastine (45) . The numerically increased gene expression for Kit ligand is of significant interest in view of the role of the gene in the function of this tyrosine kinase receptor gene in responding to growth factors such as insulin-like growth factor-1 (IGF-1) in the development of interstitial cells of Cajal, the pacemakers of the gastrointestinal tract.
The numerical downregulation of TPSAB1 (P ϭ 0.097 and q ϭ 0.144, which controls the synthesis of alpha and beta tryptases) and KYNU (P ϭ 0.131 and q ϭ 0.166 kynureninase, which metabolizes tryptophan) is similarly intriguing in the context of IBS. Beta tryptases appear to be the main isoenzymes expressed in mast cells; whereas, in basophils, alpha tryptases predominate. Tryptases are one of the main products of mast cells. Our data suggest the hypothesis that there is downregulation in the synthesis of tryptase, in contrast to several prior publications that have documented increased expression of tryptase in mucosa from patients with IBS, specifically in colonic mucosa (3, 4, 7, 15, 49) and in mRNA (21) , as well as protein expression (35) in jejunal mucosal biopsies of IBS patients. The mechanism resulting in this hypothetical reduction in tryptases is the observed numerical Fig. 4 . Cartoon summarizing altered mRNA expression in cellular elements of the descending duodenal mucosa in patients with IBS-D, based on nominal significance (P Ͻ 0.05) or statistical significance (q Ͻ 0.05: INADL, MAGI1, PPP2R5C, MAPKAPK5, TLR3, and IL-15) and including TPSBA1 (P Ͻ 0.10). TJ, tight junction; GC-C, guanylate cyclase; CFTR, cystic fibrosis transmembrane regulator. Fold upregulated mRNA is in black; downregulated is in gray. downregulation of TPSAB1; however, it is important to confirm these observations given the other data showing increased tryptase and other proteases in supernatants from (particularly) colonic biopsies from patients with IBS-D.
Kynureninase metabolizes tryptophan, and the synthesis of NAD (or NADP) and quinolic acid from tryptophan involves a series of enzymes and the formation of a number of intermediates which are collectively called "kynurenines." Kynurenic acid is a neuroprotective N-methyl D-aspartate (NMDA) antagonist (e.g., on enteric glutamatergic neurons) and an ␣ 7 -nicotinic cholinergic agonist, potentially dysregulating intestinal motility and altering mechanosensitivity (27) . In mononuclear cells, including tissue macrophages, quinolinic acid is the main end product of the kynurenine pathway and plays a role in immunoregulatory processes (37) . Recent evidence shows kyruneninase plays a role in inflammation (24) . Reduced expression of KYNU may conceivably result in greater motor dysregulation and inflammation in IBS-D due to enhanced tryptophan metabolism through the kynurenine pathway. It is also interesting to note that there were other upregulated genes in the quinolinate pathway (HAAO and QPRT).
In summary, our results extend the prior observations recorded in jejunal mucosa (35) , confirm the potential upregulation of ion transport processes observed in colonic mucosa (11, 12) , and identify potential compensatory changes in immune and barrier functions in small intestinal mucosa. However, our current studies should be regarded as pilot data that require replication in larger numbers, as well as control for BMI, enriching the current study sample with patients with a group of IBS -D patients with normal BMI, since there is evidence that obesity is associated with gastrointestinal symptoms, an inflammatory diathesis in general, as well as possible changes in intestinal permeability or bile acid malabsorption. Neverthelss, this pilot study identifies mechanisms that deserve further study and identifies the fold expression and coefficient of variation that will allow planning with adequate sample sizes in future studies. In fact, our planned hypothesis-testing study will include 60 patients with IBS-D, 30 with IBS-C, and 30 healthy controls. In addition, given the wide variations in protein expression observed, it appears that biological significance of these different mechanisms expressed in intestinal mucosa from patients with IBS-D may be interrogated in future studies using enteroids. These have the potential to provide new insights on the pathobiological mechanisms, allowing different mechanisms and pathways can be interrogated in greater depth. The observations in the current study provide a step to further understand potential etiopathogenetic mediators as well as biological pathways involved in IBS-D.
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